nrr podcast logo

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View full description +

LATEST EPISODE

08.18.26

The Story Behind LYTENAVA™: From FDA Approval to Retina Practice

In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA.

Intended for a US audience only.
Sponsored by Outlook Therapeutics

References
1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd
2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026.
3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next
4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective

Play Episode

MORE EPISODES

08.12.26

The Fellow Eye: Episode 6

Justin C. Muste, MD; David Fell, MD; Monia Reding, MD; and Benjamin Young, MD

08.05.26

ASRS '26: SOL-1 and TRUCKEE at 4.5 Years

Dilsher Dhoot, MD; and Carl Danzig, MD

07.16.26

New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal

Jordan Deaner, MD; Vaidehi Dedania, MD; and Rehan Hussain, MD

07.08.26

Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.01.26

The Fellow Eye: Episode 5

Justin C. Muste, MD; David Fell, MD; Omesh P. Gupta, MD; and Shane Griffin, MD, MCR

06.26.26

Retinal Perfusion, Sensitivity, and Function in DR

Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD

Show More